GO:0006878 intracellular copper ion homeostasis: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006878 (intracellular copper ion homeostasis) describes the biological process that maintains a steady-state level of copper ions inside the cell, preventing both copper deficiency and copper overload.
• Copper is an essential cofactor for enzymes involved in redox chemistry, mitochondrial respiration, and iron metabolism, but free copper is toxic because it drives Fenton-like reactions and oxidative stress [3,4].
• Key genes controlling intracellular copper homeostasis include SLC31A1 (CTR1) for uptake, ATP7A and ATP7B for efflux and Golgi delivery, and metallothioneins (MT1/MT2) for buffering [4,6].
• Disruption of intracellular copper homeostasis is linked to cancer, liver disease, cardiovascular fibrosis, and vascular calcification through cuproptosis and cuproplasia mechanisms [1,2,5,6,7,8].
• Cuproptosis, a copper-dependent cell death pathway, is triggered when excess copper binds lipoylated TCA cycle proteins and induces proteotoxic stress, and it can be modulated by signaling pathways such as Wnt/β-catenin [1,3].
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of copper homeostasis genes in disease and to validate therapeutic targets [1,6,8].
Description
Intracellular copper ion homeostasis (GO:0006878) is the biological process that maintains a steady-state level of copper ions within a cell, balancing uptake, distribution, storage, and efflux to avoid both deficiency and toxicity. Copper is an essential trace element that serves as a catalytic cofactor for enzymes such as cytochrome c oxidase, superoxide dismutase 1 (SOD1), and ceruloplasmin, but when labile copper accumulates it catalyzes reactive oxygen species (ROS) generation and triggers cell death pathways including cuproptosis [3,4]. Because copper is both indispensable and dangerous, cells have evolved a sophisticated network of transporters, chaperones, and chelators to keep intracellular copper within a narrow physiological range. Research into GO:0006878 has accelerated with the discovery of cuproptosis, a copper-dependent form of regulated cell death that is distinct from apoptosis, ferroptosis, and necroptosis. Dysregulated copper homeostasis is now recognized as a hallmark of multiple cancers, where high intracellular copper supports proliferation (cuproplasia) and can be exploited therapeutically by inducing cuproptosis [1,3]. In liver diseases, copper overload due to ATP7B mutations causes Wilson disease, while copper deficiency contributes to anemia and neurodegeneration. In cardiovascular disease, altered copper transport in cardiomyocytes and vascular smooth muscle cells promotes fibrosis and calcification [6,7]. Understanding the molecular players and regulatory logic of intracellular copper homeostasis is therefore critical for both basic cell biology and translational medicine. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links, and experimental models used to study GO:0006878, with a focus on how CRISPR-based editing can accelerate discovery [1,2,5,6,7,8].
intracellular copper ion homeostasis At A Glance
| GO ID | GO:0006878 |
|---|---|
| GO term | intracellular copper ion homeostasis |
| Ontology | biological_process |
| Synonym | cellular copper ion homeostasis; copper homeostasis |
| Definition | A homeostatic process involved in the maintenance of a steady state level of copper ions within a cell. |
| Major function | Maintains intracellular copper concentration within physiological limits to support cuproenzyme activity and prevent copper toxicity. |
| Key transporters | SLC31A1 (CTR1) for uptake; ATP7A and ATP7B for efflux and Golgi delivery; MT1/MT2 for buffering. |
| Associated cell death | Cuproptosis, a copper-dependent regulated cell death driven by lipoylated TCA cycle protein aggregation. |
| Disease relevance | Cancer, Wilson disease, liver disease, cardiovascular fibrosis, vascular calcification, neurodegeneration. |
What Is GO:0006878?
Intracellular copper ion homeostasis (GO:0006878) is defined by QuickGO as a homeostatic process involved in the maintenance of a steady state level of copper ions within a cell. In other words, it encompasses all cellular activities that sense, import, buffer, distribute, and export copper ions so that the cytosolic and organellar copper concentrations remain within a physiological window. This process prevents copper deficiency that would impair cuproenzyme function and avoids copper overload that would promote oxidative damage and cuproptosis [3,4].
Why Is intracellular copper ion homeostasis Important in Cell Biology?
Intracellular copper ion homeostasis is essential because copper is required for the activity of key enzymes in energy metabolism, antioxidant defense, and neurotransmitter synthesis, yet free copper is highly toxic and can trigger oxidative stress and cell death [3,4]. Disruption of this homeostasis is causally linked to inherited disorders such as Wilson disease and Menkes disease, and to acquired conditions including cancer, liver fibrosis, cardiovascular calcification, and diabetic cardiomyopathy [4,6,7]. Moreover, the recent recognition of cuproptosis as a distinct cell death modality has made copper homeostasis a high-priority target for anticancer drug development [1,2,3,5,8].
• Maintains activity of cuproenzymes such as cytochrome c oxidase, SOD1, and ceruloplasmin [3,4].
• Prevents copper-induced oxidative stress and Fenton chemistry that damage lipids, proteins, and DNA [3,4].
• Regulates cuproptosis, a copper-dependent cell death pathway with therapeutic potential in cancer [1,2,3].
• Supports cuproplasia, the copper-dependent proliferation program exploited by many tumors.
• Dysregulation causes Wilson disease (ATP7B) and Menkes disease (ATP7A).
• Contributes to liver disease progression, including steatosis, fibrosis, and hepatocellular carcinoma.
• Modulates cardiovascular pathology such as vascular calcification and diabetic cardiac fibrosis [6,7].
• Provides targets for copper-modulating nanomedicines and immunotherapies [5,8].
• Influences redox homeostasis and ferroptosis crosstalk [5,8].
• Enables CRISPR-based functional genomics of copper transporters and chaperones [1,6,8].
What Happens During intracellular copper ion homeostasis?
Copper uptake at the plasma membrane
In simple terms: Copper enters the cell through a dedicated door called CTR1.
The primary route for copper entry into cells is via SLC31A1 (CTR1), a high-affinity copper transporter on the plasma membrane. CTR1-mediated uptake is essential for supplying copper to intracellular cuproenzymes, and its expression is regulated by copper availability and cellular demands. In cancer cells, increased CTR1 expression elevates intracellular copper, supporting cuproplasia and sensitizing cells to cuproptosis inducers. Methylation of SLC31A1 exon 1 has been shown to reduce intracellular copper ion levels and promote diabetic cardiac fibrosis, illustrating how epigenetic regulation of uptake can drive disease.
Intracellular copper trafficking and chaperone delivery
In simple terms: Inside the cell, copper is handed off to chaperones that deliver it to the right enzymes.
Once inside, copper is bound by metallochaperones such as CCS (for SOD1), COX17 (for cytochrome c oxidase assembly), and ATOX1 (for ATP7A/ATP7B). These chaperones prevent free copper from participating in toxic redox reactions and ensure targeted delivery to copper-dependent enzymes. The copper chaperone network is critical for mitochondrial respiration and antioxidant defense, and its disruption leads to mitochondrial dysfunction and oxidative stress.
Copper storage and buffering by metallothioneins
In simple terms: Metallothioneins act like sponges that soak up excess copper to keep it harmless.
Metallothioneins (MT1, MT2) are cysteine-rich proteins that chelate copper and other metals, providing a buffer against copper overload. Their expression is induced by copper via the metal-responsive transcription factor MTF1, and they protect cells from copper toxicity. In cancer, high metallothionein levels can sequester copper and reduce cuproptosis sensitivity, whereas low levels favor copper-induced cell death.
Copper efflux and Golgi delivery by ATP7A and ATP7B
In simple terms: ATP7A and ATP7B are pumps that move excess copper out of the cell or into the secretory pathway.
ATP7A and ATP7B are P-type ATPases that transport copper across membranes. ATP7A is ubiquitously expressed and exports excess copper, while ATP7B is primarily hepatic and delivers copper to ceruloplasmin in the Golgi and mediates biliary excretion. Mutations in ATP7A cause Menkes disease, and mutations in ATP7B cause Wilson disease, both characterized by severe copper misdistribution. In cancer, ATP7A/ATP7B expression can influence intracellular copper levels and sensitivity to cuproptosis.
Copper-dependent cell death: cuproptosis
In simple terms: When copper levels get too high, it can trigger a specific cell death program called cuproptosis.
Excess intracellular copper binds to lipoylated components of the tricarboxylic acid (TCA) cycle, leading to their aggregation and loss of iron-sulfur cluster proteins, which induces proteotoxic stress and cell death termed cuproptosis. This process is distinct from apoptosis and ferroptosis and is dependent on mitochondrial respiration. Dysregulated Wnt/β-catenin signaling confers resistance to cuproptosis in cancer cells, linking developmental signaling to copper homeostasis. Triptolide has been shown to induce cuproptosis in cervical cancer, highlighting its therapeutic potential. Copper-driven dual cell death can also disrupt intracellular redox homeostasis and boost anti-tumor immunotherapy.
Key Genes Involved in GO:0006878 intracellular copper ion homeostasis
The following genes and proteins are central to intracellular copper ion homeostasis, encompassing uptake, trafficking, storage, efflux, and copper-dependent cell death.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC31A1 (CTR1) | High-affinity copper uptake transporter | Regulates intracellular copper levels; epigenetic silencing linked to diabetic cardiac fibrosis |
| ATP7A | Copper efflux pump; Menkes disease gene | Mutations cause copper deficiency; modulates cuproptosis sensitivity |
| ATP7B | Copper efflux and Golgi delivery; Wilson disease gene | Mutations cause copper overload and liver disease |
| MT1 (metallothionein 1) | Copper buffering and detoxification | Protects against copper toxicity; affects cuproptosis resistance |
| MT2 (metallothionein 2) | Copper buffering and detoxification | Modulates intracellular copper availability |
| CCS | Copper chaperone for SOD1 | Delivers copper to SOD1; links copper homeostasis to antioxidant defense |
| COX17 | Copper chaperone for cytochrome c oxidase | Essential for mitochondrial respiration |
| ATOX1 | Copper chaperone for ATP7A/ATP7B | Facilitates copper delivery to efflux pumps |
| FDX1 | Ferredoxin 1; reduces Cu(II) to Cu(I) | Key mediator of cuproptosis; regulated by PPAR-γ signaling |
| LIAS | Lipoyl synthase | Required for lipoylation of TCA cycle enzymes targeted by copper |
| DLAT | Dihydrolipoamide S-acetyltransferase | Lipoylated target of copper-induced aggregation in cuproptosis |
| SOD1 | Cu/Zn superoxide dismutase | Requires copper for activity; protects against oxidative stress |
| MTF1 | Metal-responsive transcription factor 1 | Induces metallothionein expression in response to copper |
| PPAR-γ | Nuclear receptor regulating FDX1 | Modulates cuproptosis and vascular calcification |
| Wnt/β-catenin pathway | Developmental signaling | Dysregulation confers cuproptosis resistance |
| Elabela | Endogenous peptide | Alleviates cuproptosis and vascular calcification via PPAR-γ/FDX1 |
How Is intracellular copper ion homeostasis Regulated?
Intracellular copper ion homeostasis is regulated at multiple levels. Transcriptional control is mediated by metal-responsive transcription factor 1 (MTF1), which induces metallothioneins and other copper-responsive genes upon copper excess. Post-translational regulation includes copper-dependent trafficking of ATP7A and ATP7B between the trans-Golgi network and the plasma membrane, as well as degradation of CTR1 under high copper conditions. Signaling pathways such as Wnt/β-catenin can modulate cuproptosis sensitivity, thereby influencing copper homeostasis indirectly. The PPAR-γ/FDX1 axis regulates cuproptosis and vascular calcification, linking lipid signaling to copper-dependent cell death. Additionally, epigenetic mechanisms such as SLC31A1 exon 1 methylation can reduce copper uptake and alter disease phenotypes.
intracellular copper ion homeostasis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATP7B | Wilson disease; copper overload in liver | Atp7b knockout mice; patient-derived hepatocytes; CRISPR knock-in of patient mutations |
| SLC31A1 | Diabetic cardiac fibrosis; reduced copper uptake | Cardiomyocyte-specific Slc31a1 knockout mice; methylation-edited cell lines |
| FDX1 | Vascular calcification; cuproptosis | Fdx1 knockout mice; vascular smooth muscle cell overexpression models |
| Wnt/β-catenin | Cuproptosis resistance in cancer | Cancer cell lines with β-catenin knockout or overexpression; xenograft models |
| MT1/MT2 | Copper buffering; cancer chemoresistance | Metallothionein knockout and overexpression cell lines; tumor xenografts |
Cancer and cuproptosis
Many cancers exhibit elevated intracellular copper to support proliferation (cuproplasia), but this also creates a vulnerability to cuproptosis inducers. Dysregulated Wnt/β-catenin signaling confers resistance to cuproptosis in cancer cells, suggesting that pathway inhibitors could sensitize tumors to copper-based therapies. Triptolide induces cuproptosis in cervical cancer, demonstrating a novel antitumor strategy. Copper-driven dual cell death can disrupt redox homeostasis and enhance anti-tumor immunotherapy. Cascade-targeting copper homeostasis nano-regulators have been developed for breast cancer therapy by boosting cuproptosis and ferroptosis.
Liver diseases
Copper metabolism is critical for liver health, and its dysregulation contributes to Wilson disease, non-alcoholic fatty liver disease, and hepatocellular carcinoma. ATP7B mutations cause copper overload in hepatocytes, leading to oxidative stress, inflammation, and fibrosis. Mechanisms of copper metabolism and cuproptosis are being actively investigated as therapeutic targets for liver diseases.
Cardiovascular disease
SLC31A1 exon 1 methylation reduces intracellular copper ion levels and promotes diabetic cardiac fibrosis, linking copper deficiency to cardiac pathology. Elabela alleviates cuproptosis and vascular calcification in vitamin D3-overloaded mice via regulation of the PPAR-γ/FDX1 signaling axis. These findings highlight copper homeostasis as a modifiable process in cardiovascular disease [6,7].
From intracellular copper ion homeostasis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC31A1 alter intracellular copper and cardiac fibrosis? | Cardiomyocyte-specific Slc31a1 knockout mouse; CRISPR KO in cardiac fibroblasts |
| Does a specific ATP7B mutation cause copper overload? | CRISPR point-mutation knock-in of ATP7B patient variants in hepatocyte-like cells |
| Does overexpression of MT1 protect against cuproptosis? | MT1 overexpression cell lines; cuproptosis induction assays |
| Does FDX1 mediate PPAR-γ-dependent vascular calcification? | Fdx1 knockout and knock-in models; vascular smooth muscle cells |
| Can Wnt/β-catenin inhibition sensitize tumors to cuproptosis? | β-catenin knockout cancer cells; xenograft with cuproptosis inducers |
| Does ATOX1 tagging affect copper delivery to ATP7A/ATP7B? | Endogenous ATOX1 knock-in with fluorescent tag; live-cell imaging |
How to Study the intracellular copper ion homeostasis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes | Expression of copper homeostasis genes under stress |
| Methylation-specific PCR | DNA methylation status | SLC31A1 exon 1 methylation in diabetic cardiac fibrosis |
| ICP-MS | Total intracellular copper content | Quantification of copper levels after knockout or treatment |
| Fluorescent copper sensors | Labile copper pools | Live-cell imaging of copper dynamics |
| Proteomics | Protein aggregation and abundance | Detection of lipoylated TCA cycle protein aggregates in cuproptosis |
| Seahorse assay | Mitochondrial respiration | Assessment of metabolic dependence of cuproptosis |
| Cell viability with copper ionophores | Cuproptosis sensitivity | Drug screening and genetic validation [1,2,3] |
| Xenograft/syngeneic tumor models | In vivo tumor growth and immune response | Testing copper-based therapies and immunotherapy [5,8] |
Genomic and transcriptomic profiling
RNA-seq and single-cell RNA-seq can quantify expression of copper homeostasis genes (SLC31A1, ATP7A, ATP7B, MT1, MT2, FDX1, LIAS) across conditions and cell types [4,6]. Methylation-specific PCR and bisulfite sequencing can assess epigenetic regulation such as SLC31A1 exon 1 methylation. CRISPR screening coupled with RNA-seq can identify genes that modify copper sensitivity.
Proteomic and metalloproteomic approaches
Proteomics can detect copper-induced aggregation of lipoylated TCA cycle proteins (DLAT, PDHA1) during cuproptosis. Metalloproteomics using ICP-MS or X-ray fluorescence can quantify intracellular copper and its distribution among proteins. Western blotting for FDX1, ATP7A, ATP7B, and metallothioneins provides validation [4,7].
Imaging and live-cell assays
Fluorescent copper sensors (e.g., CS3, Copper-Green) enable real-time visualization of labile copper in live cells. Tagged knock-in of ATOX1 or ATP7B with fluorescent proteins allows tracking of copper trafficking. Mitochondrial function can be assessed with Seahorse and MitoSOX to link copper to respiration and ROS.
Functional assays for cuproptosis and cell death
Cuproptosis is measured by cell viability assays with copper ionophores (e.g., elesclomol) and rescue with copper chelators. TUNEL, Annexin V, and lipid peroxidation assays distinguish cuproptosis from apoptosis and ferroptosis [3,5]. Immunotherapy efficacy can be tested in syngeneic tumor models with copper-driven dual cell death inducers.
How CRISPR Can Be Used to Study GO:0006878 intracellular copper ion homeostasis
Knockout
CRISPR knockout of copper homeostasis genes such as SLC31A1, ATP7A, ATP7B, MT1, MT2, FDX1, and LIAS can reveal their causal roles in copper uptake, efflux, buffering, and cuproptosis [1,3,4]. For example, SLC31A1 knockout reduces intracellular copper and can protect against cuproptosis, while FDX1 knockout confers resistance to copper-induced cell death. Knockout models are also used to validate targets in liver disease and cardiovascular fibrosis [4,6].
Point Mutation
CRISPR point-mutation knock-in can model disease-associated variants such as ATP7B mutations in Wilson disease or SLC31A1 mutations affecting copper transport [4,6]. These models allow precise interrogation of how single amino acid changes alter copper binding, transport kinetics, and downstream pathology. Point mutations in FDX1 or LIAS can dissect their roles in cuproptosis.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous loci (e.g., ATOX1-GFP, ATP7B-HA) enables real-time tracking of copper chaperone and transporter dynamics. Knock-in of patient-specific mutations into hepatocyte-like cells or cardiomyocytes provides isogenic models for drug testing [4,6]. Knock-in of copper-responsive reporters can be used for high-throughput screening.
Overexpression
Overexpression of metallothioneins (MT1, MT2) or ATP7A/ATP7B can buffer intracellular copper and protect against cuproptosis, while overexpression of SLC31A1 increases copper uptake and sensitizes cells to copper-induced death [3,4]. Overexpression models are useful for testing whether a gene is sufficient to alter copper homeostasis and disease phenotypes [6,7].
How EDITGENE Supports intracellular copper ion homeostasis Research
Researchers studying intracellular copper ion homeostasis-related genes often need to determine whether a candidate gene is causally involved in copper handling, cuproptosis, or disease progression. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional validation of copper homeostasis targets [1,2,5,6,7,8].
Contact EDITGENE today to design your custom CRISPR model for intracellular copper ion homeostasis research.
Frequently Asked Questions About intracellular copper ion homeostasis
What is intracellular copper ion homeostasis?
Intracellular copper ion homeostasis (GO:0006878) is the biological process that maintains a steady-state level of copper ions within a cell, balancing uptake, storage, trafficking, and efflux to support cuproenzyme function and prevent copper toxicity [3,4].
What genes are involved in intracellular copper ion homeostasis?
Key genes include SLC31A1 (CTR1) for uptake, ATP7A and ATP7B for efflux, metallothioneins (MT1, MT2) for buffering, and chaperones such as CCS, COX17, and ATOX1 [4,6].
How is copper transported into cells?
Copper enters cells primarily through SLC31A1 (CTR1), a high-affinity copper transporter on the plasma membrane.
What is cuproptosis?
Cuproptosis is a copper-dependent form of regulated cell death triggered by excess intracellular copper binding to lipoylated TCA cycle proteins, leading to proteotoxic stress.
How does copper homeostasis relate to cancer?
Cancer cells often have elevated copper to support proliferation (cuproplasia), but this also creates sensitivity to cuproptosis inducers; Wnt/β-catenin signaling can confer resistance [1,3].
What diseases are linked to copper homeostasis defects?
Wilson disease (ATP7B mutations), Menkes disease (ATP7A mutations), liver disease, diabetic cardiac fibrosis, and vascular calcification are linked to copper homeostasis defects [4,6,7].
How can CRISPR be used to study copper homeostasis?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow causal testing of copper transporters, chaperones, and metallothioneins in disease and cell death pathways [1,3,4,6].
What methods measure intracellular copper levels?
ICP-MS, fluorescent copper sensors, and metalloproteomics can quantify total and labile copper pools in cells and tissues.
What is the role of metallothioneins in copper homeostasis?
Metallothioneins (MT1, MT2) are cysteine-rich proteins that chelate excess copper, providing a buffer against toxicity and modulating cuproptosis sensitivity [3,4].
How does SLC31A1 methylation affect copper homeostasis?
Methylation of SLC31A1 exon 1 reduces intracellular copper ion levels and has been linked to diabetic cardiac fibrosis.
Conclusion
Intracellular copper ion homeostasis (GO:0006878) is a fundamental biological process that safeguards cells against copper deficiency and overload while supporting essential cuproenzyme functions [3,4]. Its dysregulation is implicated in cancer, liver disease, cardiovascular pathology, and inherited disorders, and the emergence of cuproptosis has opened new therapeutic avenues [1,2,3,5,6,7,8]. CRISPR-based models are indispensable for dissecting the causal roles of copper transporters, chaperones, and metallothioneins, and for validating new drug targets. EDITGENE offers comprehensive CRISPR services to accelerate this research and translate copper biology into clinical benefit.
References
- 1. Liu YT et al.. 2024. Dysregulated Wnt/β-catenin signaling confers resistance to cuproptosis in cancer cells.. Cell Death Differ 31(11):1452-1466 PMID: 38987382
- 2. Xiao Y et al.. 2024. Triptolide-induced cuproptosis is a novel antitumor strategy for the treatment of cervical cancer.. Cell Mol Biol Lett 29(1):113 PMID: 39198750
- 3. Lu K et al.. 2025. Cuproplasia and cuproptosis, two sides of the coin.. Cancer Commun (Lond) 45(5):505-524 PMID: 39865459
- 4. Chen H et al.. 2025. Mechanisms of copper metabolism and cuproptosis: implications for liver diseases.. Front Immunol 16:1633711 PMID: 40808953
- 5. Wang Z et al.. 2026. Disrupting intracellular redox homeostasis through copper-driven dual cell death to induce anti-tumor immunotherapy.. Biomaterials 324:123523 PMID: 40592037
- 6. Song K et al.. 2026. SLC31A1 exon 1 methylation reduces intracellular copper ion and promotes diabetic cardiac fibrosis.. Cardiovasc Diabetol 25(1) PMID: 41776560
- 7. Qi RQ et al.. 2024. Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling.. Mol Med 30(1):223 PMID: 39567863
- 8. Liang X et al.. 2025. Cascade-targeting copper homeostasis nano-regulators for mild-photothermal boosted cuproptosis/ferroptosis mediated breast cancer therapy.. J Nanobiotechnology 23(1):651 PMID: 41074159
